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A BST R AC T   
 
Aim: The causes of prostate cancer development and molecular mechanism underlying its 
development and progression are not clearly understood. The aim of this study is to determine the 
frequency of G1733A (rs6152) polymorphism of the androgen receptor (AR) gene among patients 
with prostate cancer, and to examine the role of this polymorphism in the development of prostate 
cancer. 
Method: DNA samples isolated from 96 individuals (49 patients with prostate cancer and 47 controls) 
were analyzed with real time-polymerase chain reaction (real time-PCR) in order to determine 
G1733A (rs6152) polymorphism genotypes and allele frequencies in the AR gene. The results were 
evaluated statistically.  
Results: Genotype frequency was determined as 91% GG and 9% AG among the controls, and 67% 
GG and 33% AG among the patients. G allele frequency was 95% in controls and 83% in patients, 
whereas A allele frequency was 5% in controls and 17% in patients. There was a statistically 
significant difference between patient and control groups regarding genotype frequency (p<0.05). 
Conclusion: Based on the results of our study, we can infer that G1733A (rs6152) polymorphism of 
the AR gene plays a role in development of prostate cancer in the Turkish population. 
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Introduction 
Prostate cancer is the most common cancer in 
men, and it is the 2nd leading cause of death in 
the whole world [1]. Despite its clinical 
significance and high prevalence, the actual 
causes of development and molecular 
mechanism underlying its development and 
progression are not clearly understood [2, 3]. 
Studies have examined the role of possible 
factors such as ethnicity, regional variations, 
dietary habits and androgen levels [4, 5]. 
Among these factors, although steroid 
hormones and especially androgens seem to 
have a major role, the exact effect is not fully 
clear. Epidemiological studies examining the 
effects of androgens on prostate cancer have 
controversial results [6]. Genetic studies on 
prostate cancer suggest that the genetic 
polymorphisms of testosterone and other 
androgens especially might affect androgen 
metabolism. For example, a polymorphism 
found in CYP3A4, which has a role in 
testosterone metabolism, has been shown to 
create a tendency towards prostate cancer [7]. 
Although there are a lot of CYP genes and 
enzymes, only the enzymes belonging to 
CYP1, CYP2 and CYP3 families have been 
found to play major roles in drug metabolism; 
therefore it has been proposed that pharmaco-
genetically they may be polymorphisms that 
might create a tendency towards cancer 
development. Additionally, other CYP families 
have essential roles in intermediate 
metabolisms [8]. In the CYP2C subfamily, 
CYP2C9 and CYP2C19 enzymes show 
polymorphism and have significant roles in 
metabolism [9]. Additionally, CYP3A4 
polymorphism causes a tendency towards 
prostate cancer especially in the Caucasian 
race. Individuals carrying the polymorphic G 
allele have 6 times higher risk of developing 
prostate cancer [10]. 
The androgen receptor (AR) gene is a 
transcription factor regulating the 
physiological actions of androgens. AR gene is 
localized between Xq11-q12 in the long arm X 
chromosome, and contains eight exons [11, 
12]. AR's belong to the family of steroid 
hormone receptors, and these hormones 
include glucocorticoids, mineralocorticoids, 
thyroid hormone, retinol, estrogen and 
progesterone. Once the androgen enters the 
cell, it binds to the AR. Subsequently, this 
complex is transferred to the nucleus, and 
binds specific regions in the DNA and initiates 
mRNA synthesis [13, 14]. Exon 1 of the AR 
gene includes two polymorphic trinucleotide 
repeats (CAG and GGC) that encode 
polyglutamine and polyglycine. In vitro 
studies have shown that the length of these 
repeat sequences is associated with AR activity 
[15, 16]. Additionally, a single nucleotide 
polymorphism has previously been described, 
in which G is converted to A (G1733A) in the 
3rd nucleotide position of 211th codon 
between these two repeats [17]. 
The aim of the present study is to determine the 
frequency of G1733A (rs6152) polymorphism 
of the AR gene in patients diagnosed with 
prostate cancer. 
 
Methods 
The study group consisted of 49 cases 
clinically diagnosed with prostate cancer 
(Group 2) by the Urology Department of the 
Faculty of Medicine in Bolu Abant İzzet 
Baysal University. The control group (Group 
1) consisted of a total of 47 healthy men aged 
over 50 years old, who did not have genetic 
relationship between them. The control group 
included 46 individuals who had normal 
prostate-specific antigen (PSA) levels 
according to their age, and did not show any 
abnormal findings during their digital rectal 
Yagli et al.  Exp Biomed Res 2018; 1(4):128-134 
   
 
130 
 
examination, together with 1 case who had a 
PSA level of 14 ng/mL, and whose pathology 
result of the prostate gland biopsy specimen 
was reported as benign prostate hyperplasia 
(BPH). 
Genomic DNA was manually isolated from 3 
ml blood samples using High Pure PCR 
Template Preparation Kit (Roche Applied 
Science, Germany). G1733A (rs6152) 
polymorphism of the AR gene was analyzed 
with Light Cycler 480 device using 
LightCycler Hybridization Probe Kit. After 
PCR amplification with LightCycler 480 
device, homozygous wildtype, homozygous 
polymorphic and heterozygous genotypes 
were identified based on the degree of Tm 
peaks in melting curve analysis (Tm: In 
melting curve analysis, the temperature of 
double-stranded DNA sample is gradually 
increased, and the change in the fluorescence 
signal is plotted against temperature. The 
peaks caused by sudden decreases in the 
fluorescence signal indicate separation of the 
DNA strands from each other). While 
heterozygous genotype has two peaks at one 
Tm degree, homozygous polymorphic 
genotypes have two peaks at two different Tm 
degrees. These were Tm1: 55.16 °C for Allele 
A, and Tm2: 63.55 °C for Allele G. Statistical 
analysis was performed with SPSS ver.15 
(Statistical Package for Social Sciences) 
package software. Results were evaluated 
using chi-square and Fisher's exact test. P<0.05 
was accepted as statistically significant. 
 
Results 
The control group including healthy 
individuals had a mean age of 67.93 (51-86) 
years, and mean PSA level of 2.04 ng/mL (0.1 
– 14). The study group including patients 
diagnosed with prostate cancer had a mean age 
of 72.38 (49-86) years and a mean PSA level 
of 37.63 ng/mL (4.5 – 150). 
AR gene G1733A (rs6152) genotype 
frequency was found as 91% GG and 9% AG 
in the control group, and 67% GG and 33% AG 
in the patient group. G allele frequency was 
95% in Group 1 and 83% in Group 2, whereas 
A allele frequency was 5% in Group 1 and 17% 
in Group 2. There were statistically significant 
differences between the groups regarding 
genotype frequencies (p<0.05) (Table 1). 
 
Table 1. Distribution of androgene receptor 
gene G1733A (rs6152) genotype and allele 
between groups. 
 
PSA: prostate-specific antigen. 
*X2 test, P =0.004. **Fisher exact test, P =0.005. 
Discussion 
Studies that investigate the genetic basis of 
prostate cancer provide important clues to 
understand the nature of this cancer type and 
offer treatment strategies. Significant advances 
in the fields of molecular biology and 
epidemiology have widened the horizons in 
biology and etiology of this cancer. Although 
the etiopathogenesis of prostate cancer is not 
fully clear, the evidence suggests the disease is 
multifactorial [18]. 
Androgens are the major sex hormones in 
males, and they are responsible for secondary 
differentiation. Androgens exert their actions 
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through AR, which is a ligand-dependent 
nuclear transcription factor. AR has an 
oncogenic potential, and plays an important 
role in development of prostate cancer [19]. 
The first exon of the AR gene is very 
polymorphic and contains CAG and GGC 
repeat sequences. The most important factor in 
development of prostate cancer is advanced 
age [20]. Several studies have found 
associations between prostate cancer and short 
CAG repeats; on the other hand, some other 
studies could not find an association between 
prostate cancer and CAG length [21, 22]. 
Over 300 somatic and germ line mutations 
have been described for AR-related diseases. 
While AR mutations cause androgen 
insensitivity syndrome, they result in 
hypersensitivity and increased receptor 
function in prostate cancer cells [23]. Length 
of CAG repeats generally vary from 11 to 31 
copies; however it was found to be shorter in 
African Americans [15]. While some studies 
investigating the relationship between CAG 
repeats and stage of prostate cancer have found 
longer repeats in patients with advanced stage 
disease, others did not detect a difference in 
CAG repeats [24-27]. Zhai et al. studied the 
Han population and reported that development 
and progression of prostate cancer was 
intensified as the number of CAG repeats in 
AR gene decreased [28]. Biolchi et al. 
examined the effect of GGC repeats in the AR 
gene on development of prostate cancer and 
BPH in the Brazilian population. They found 
that individuals with numbers of GGC repeats 
>19 had higher testosterone levels, BPH 
frequency and prostate cancer rates [29]. 
Single point mutations can sometimes lead to 
shifts, increases or decreases in repeat 
sequences. These mutations can also increase 
the cancer risk directly [10]. A polymorphism 
in the CYP3A4 which functions in testosterone 
metabolism was shown to create a tendency 
towards prostate cancer [7]. Additionally, 
similar to our study, Esteban et al. detected 
G1733A (rs6152) polymorphism in prostate, 
breast, colon and esophagus cancers in 
Mediterranean countries [30]. The same study 
showed that frequency of polymorphism 
increased in the normal population as we move 
from North Mediterranean towards Europe. 
Francesco et al. examined, the genotype A of 
the androgen receptor (AR) gene rs6152, 
which was presented in 45 (18.2%) patients, 
was the only gene significantly associated with 
an increased risk of prostate cancer pathologic 
grade group 4-5 and pT3b/4 disease (all 
p<0.05) [31]. 
In another study, Fernandes et al examined that 
Rs743572, rs6162, rs6163, rs1256049 and 
rs2293275 are promising biomarkers for 
Prostate Cancer aggression but they did not 
find any significant association with Prostate 
cancer for G1733A (rs6152) and rs9332969 
[32]. 
When limitations of our study are considered, 
first of all control group is not with a 
previously negative prostate biopsy. Another 
limitation is that study group seems very 
heterogeneous in relation with the PSA values 
(4,5-150). But it is known that the positive 
predictive value was 24 % when PSA was 
suspicious but digital rectal examination was 
not, only 10% when digital rectal examination 
was suspicious but PSA was not and 49% when 
both tests were suspicious [33]. 
Our study is the first study from Turkey to 
examine the relationship between prostate 
cancer and G1733A (rs6152) polymorphism of 
the AR gene. Based on our findings, we can say 
that G1733A (rs6152) polymorphism of the 
AR gene might play a role in the development 
of prostate cancer in the Turkish population. 
We believe our results will guide future 
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studies, and studies with larger sample sizes 
would support our results. 
 
Conclusion 
As a result of our study, we can infer that 
G1733A (rs6152) polymorphism of the AR 
gene plays a role in development of prostate 
cancer in the Turkish population. Prospective 
new researches are needed to assess and 
support the role of G1733A (rs6152) 
polymorphism of the AR gene. 
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